|
Alkermes, Inc. (NASDAQ: ALKS) today announced topline results from a phase 2 clinical study of ALKS 33 in the treatment of binge eating disorder. This randomized, double-blind, placebo-controlled, 12-week study was designed to assess the safety and efficacy of daily oral administration of ALKS 33 or placebo in 68 patients with binge eating disorder... ... |
Do you like this article?
Post a comment:
Source: http://www.medicalnewstoday.com/releases/230751.php
This article was readed 422 time/s
Same article in German:
Same article in French:
Same article in Italian:
Same article in Swedish:
Same article in Spanish:
Tags: health, news, designed, assess, week, controlled, double, blind, safety, efficacy, patients, with, or, administration, daily, oral, Alkermes, randomized, announced, topline, today, NASDAQ, Inc, results, phase, clinical, treatment, eating, placebo, binge, disorder, study, ALKS



